Acta Diabetologica

, Volume 50, Issue 6, pp 965–969 | Cite as

Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs

  • Loredana Fiorentino
  • Michele Cavalera
  • Maria Mavilio
  • Francesca Conserva
  • Rossella Menghini
  • Loreto Gesualdo
  • Massimo Federici
Original Article


Diabetic nephropathy (DN) is the major cause of chronic kidney disease in developed countries and contributes significantly to increased morbidity and mortality among diabetic patients. Morphologically, DN is characterized by tubulo-interstitial fibrosis, thickening of the glomerular basement membrane and mesangial expansion mainly due to accumulation of extracellular matrix (ECM). ECM turnover is regulated by metalloproteinases and tissue inhibitors of metalloproteinases (TIMPs) activities. In diabetic conditions, TIMP3 expression in kidney is strongly reduced, but the causes of this reduction are still unknown. The aim of this study was to elucidate at least one of these mechanisms which relies on differential expression of TIMP3-targeting microRNAs (miRs) in a hyperglycemic environment either in vitro (MES13 cell line) or in vivo (mouse kidney and human biopsies). Among the TIMP3-targeting miRs, miR-21 and miR-221 were significantly upregulated in kidneys from diabetic mice compared to control littermates, and in a mesangial cell line grown in high glucose conditions. In human samples, only miR-21 expression was increased in kidney biopsies from diabetic patients compared to healthy controls. The expression of miR-217, which targets TIMP3 indirectly through downregulation of SirT1, was also increased in diabetic kidney and MES13 cell line. In agreement with these result, SirT1 expression was reduced in mouse and human diabetic kidneys as well as in MES13 mesangial cell line. TIMP3 deficiency has recently emerged as a hallmark of DN in mouse and human. In this study, we demonstrated that this reduction is due, at least in part, to increased expression of certain TIMP3-targeting miRs in diabetic kidneys compared to healthy controls. Unveiling the post-transcriptional mechanisms responsible for TIMP3 downregulation in hyperglycemic conditions may orient toward the use of this protein as a possible therapeutic target in DN.


Diabetic Nephropathy MicroRNA TIMP3 SirT1 



Tissue inhibitor of metalloproteinases


Diabetic nephropathy






Polymerase chain reaction


  1. 1.
    Ford BM, Eid AA, Gooz M, Barnes JL, Gorin YC, Abboud HE (2013) ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice. Am J Physiol Renal Physiol. doi:10.1152/ajprenal.00522.2012
  2. 2.
    Basu R, Lee J, Wang Z et al (2012) Loss of TIMP3 selectively exacerbates diabetic nephropathy. Am J Physiol Renal Physiol 303:F1341–F1352PubMedCrossRefGoogle Scholar
  3. 3.
    Chodavarapu H, Grobe N, Somineni HK, Salem ES, Madhu M, Elased KM (2013) Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLoS One 8:e62833PubMedCrossRefGoogle Scholar
  4. 4.
    Kassiri Z, Oudit GY, Kandalam V et al (2009) Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol 20:1223–1235PubMedCrossRefGoogle Scholar
  5. 5.
    Kawamoto H, Yasuda O, Suzuki T et al (2006) Tissue inhibitor of metalloproteinase-3 plays important roles in the kidney following unilateral ureteral obstruction. Hypertens Res 29:285–294PubMedCrossRefGoogle Scholar
  6. 6.
    Federici M, Hribal ML, Menghini R et al (2005) Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Investig 115:3494–3505PubMedCrossRefGoogle Scholar
  7. 7.
    Fiorentino L, Vivanti A, Cavalera M et al (2010) Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology (Baltimore, MD) 51:103–110CrossRefGoogle Scholar
  8. 8.
    Menghini R, Menini S, Amoruso R et al (2009) Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136(663–672):e664Google Scholar
  9. 9.
    Cardellini M, Menghini R, Martelli E et al (2009) TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 58:2396–2401PubMedCrossRefGoogle Scholar
  10. 10.
    Cardellini M, Menghini R, Luzi A et al (2011) Decreased IRS2 and TIMP3 expression in monocytes from offspring of type 2 diabetic patients is correlated with insulin resistance and increased intima-media thickness. Diabetes 60:3265–3270PubMedCrossRefGoogle Scholar
  11. 11.
    Menghini R, Casagrande V, Menini S et al (2012) TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. Diabetes 61:454–462PubMedCrossRefGoogle Scholar
  12. 12.
    Casagrande V, Menghini R, Menini S et al (2012) Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 32:74–81PubMedCrossRefGoogle Scholar
  13. 13.
    Menghini R, Uccioli L, Vainieri E et al (2013) Expression of tissue inhibitor of metalloprotease 3 is reduced in ischemic but not neuropathic ulcers from patients with type 2 diabetes mellitus. Acta Diabetol. doi:10.1007/s00592-013-0478-6
  14. 14.
    Gohda T, Niewczas MA, Ficociello LH et al (2012) Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 23:516–524PubMedCrossRefGoogle Scholar
  15. 15.
    Niewczas MA, Gohda T, Skupien J et al (2012) Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23:507–515PubMedCrossRefGoogle Scholar
  16. 16.
    Fernandez-Real JM, Vendrell J, Garcia I, Ricart W, Valles M (2012) Structural damage in diabetic nephropathy is associated with TNF-alpha system activity. Acta Diabetol 49:301–305PubMedCrossRefGoogle Scholar
  17. 17.
    Fiorentino L, Cavalera M, Menini S et al (2013) Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay. EMBO Mol Med 5:441–455PubMedCrossRefGoogle Scholar
  18. 18.
    Kong L, Zhu J, Han W et al (2011) Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol 48:61–69PubMedCrossRefGoogle Scholar
  19. 19.
    Saal S, Harvey SJ (2009) MicroRNAs and the kidney: coming of age. Curr Opin Nephrol Hypertens 18:317–323PubMedCrossRefGoogle Scholar
  20. 20.
    Kantharidis P, Wang B, Carew RM, Lan HY (2011) Diabetes complications: the microRNA perspective. Diabetes 60:1832–1837PubMedCrossRefGoogle Scholar
  21. 21.
    Alvarez ML, DiStefano JK (2013) Towards microRNA-based therapeutics for diabetic nephropathy. Diabetologia 56:444–456PubMedCrossRefGoogle Scholar
  22. 22.
    Kato M, Putta S, Wang M et al (2009) TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 11:881–889PubMedCrossRefGoogle Scholar
  23. 23.
    Gabriely G, Wurdinger T, Kesari S et al (2008) MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 28:5369–5380PubMedCrossRefGoogle Scholar
  24. 24.
    Lu Y, Roy S, Nuovo G et al (2011) Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 286:42292–42302PubMedCrossRefGoogle Scholar
  25. 25.
    Menghini R, Casagrande V, Cardellini M et al (2009) MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation 120:1524–1532PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2013

Authors and Affiliations

  • Loredana Fiorentino
    • 1
  • Michele Cavalera
    • 1
  • Maria Mavilio
    • 1
  • Francesca Conserva
    • 2
  • Rossella Menghini
    • 1
  • Loreto Gesualdo
    • 2
  • Massimo Federici
    • 1
    • 3
  1. 1.Department of Systems MedicineUniversity of Rome “Tor Vergata”RomeItaly
  2. 2.Department of Emergency and Organ TransplantationUniversity of BariBariItaly
  3. 3.Center for AtherosclerosisUniversity Hospital Tor VergataRomeItaly

Personalised recommendations